What is azenosertib (ZN-c3)?

Azenosertib (ZN-c3) is an investigational WEE1 inhibitor being studied in clinical trials for the treatment of ovarian cancer and other solid tumors.

Is azenosertib approved by the FDA?

No. Azenosertib is an investigational therapy and has not been approved by the U.S. Food and Drug Administration.

Where can I find information about Zentalis clinical trials?

Information about ongoing and completed clinical trials can be found on ClinicalTrials.gov and the Zentalis website.

more convenient, targeted treatment.

A New Type of Medicine

Our investigational lead candidate, azenosertib, has the potential to deliver on the promise of WEE1 inhibition in cancer therapy.

Our pipeline is focused on advancing potential first-in-class WEE1 inhibitor azenosertib as a monotherapy for Cyclin E1-positive platinum-resistant ovarian cancer, our lead indication.

Cyclin E1-Positive PROC Monotherapy (lead indication)

DENALI

DENALI Part 1b

Demonstrated Cyclin E1 protein overexpression as biomarker predicting response to azenosertib

DENALI Part 2a + Part 2b + Part 2c

Registration-intent
Cyclin E1+
FDA Fast Track Designation

In Long-term Follow-up Only

Currently enrolling part 2b

ASPENOVA

Azenosertib vs. SOC chemo

Randomized, confirmatory trial
Cyclin E1+

Currently enrolling

Ovarian Cancer Combination Therapy

MUIR

Part 2: Azenosertib + bevacizumab (in earlier lines of OC)
Part 1: Azenosertib + multiple chemo backbones (in PROC, completed)

Currently enrolling part 2

Cyclin E1-Positive PROC Monotherapy (lead indication)

DENALI

DENALI Part 1b

Demonstrated Cyclin E1 protein overexpression as biomarker predicting response to azenosertib

Status

In Long-term Follow-up Only

DENALI Part 2a + Part 2b + Part 2c

Registration-intent Cyclin E1+ FDA Fast Track Designation

Status

Currently enrolling part 2b

ASPENOVA

Azenosertib vs. SOC chemo

Randomized, confirmatory trial
Cyclin E1+

Status

Currently enrolling

Ovarian Cancer Combination Therapy

MUIR

Part 2: Azenosertib + bevacizumab (in earlier lines of OC)
Part 1: Azenosertib + multiple chemo backbones (in PROC, completed)

Status

Currently enrolling part 2

Ongoing Study

Planned Study

Results from pre-clinical and clinical studies support the ongoing development of azenosertib as both a monotherapy and combination agent across a number of oncology indications.

extending potential for azenosertib.

MORE CHOICE. MORE POSSIBILITY.

We see broad franchise potential for azenosertib across tumor types, including those driven by oncogenes that induce replication stress and those that harbor loss of function of tumor suppressors associated with cell cycle regulation.

Investigators have expressed great interest in further development of azenosertib beyond ovarian cancer due to its orthogonal, complimentary nature to cytotoxic agents, such as chemotherapy, and its ability to selectively target WEE1, a master cell regulator. Zentalis is currently supporting an investigator-sponsored trial and is interested in further development of azenosertib beyond ovarian cancer.

Discover azenosertib clinical trials